Clinical Trials

Sundance Pharmaceuticals is preparing to launch the first U.S. and Canadian clinical trials using novel cannabis strains to determine efficacy in treating acute respiratory distress syndrome in COVID-19 hospitalized patients. Sundance is also clinically studying the novel cannabis strains in the form of a nasal spray to confirm the degree to which they may reduce the risk of or prevent COVID-19 infections. The trials are slated to begin July of 2020. Initial trails will be in locations of high risk and minority populations.